Research programme: tubulin polymerisation inhibitors - Threshold PharmaceuticalsAlternative Names: TH-337; TH-482; TH-494
Latest Information Update: 19 Aug 2009
At a glance
- Originator Threshold Pharmaceuticals
- Mechanism of Action Capillary permeability stimulants; Tubulin polymerisation inhibitors; Vascular disrupting agents
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 09 May 2007 Preclinical trials in Cancer in USA (unspecified route)